Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 7,530 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Mauro Ferrari sold 7,530 shares of the stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the transaction, the director directly owned 69,053 shares of the company’s stock, valued at approximately $4,833,710. The trade was a 9.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mauro Ferrari also recently made the following trade(s):

• On Friday, November 28th, Mauro Ferrari sold 8,750 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $56.39, for a total transaction of $493,412.50.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR traded down $2.37 during trading on Tuesday, hitting $67.25. 1,334,299 shares of the company were exchanged, compared to its average volume of 2,139,110. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $72.36. The company has a market capitalization of $9.14 billion, a P/E ratio of -840.52 and a beta of 1.28. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43. The business’s 50 day moving average is $52.38 and its 200-day moving average is $33.56.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently bought and sold shares of the business. iSAM Funds UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $29,000. Salomon & Ludwin LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $34,000. Federated Hermes Inc. acquired a new stake in Arrowhead Pharmaceuticals during the third quarter worth approximately $52,000. Smartleaf Asset Management LLC increased its holdings in Arrowhead Pharmaceuticals by 2,186.5% in the third quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,618 shares in the last quarter. Finally, Virtus Advisers LLC acquired a new position in Arrowhead Pharmaceuticals in the second quarter valued at approximately $34,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARWR has been the subject of several research reports. Bank of America increased their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Piper Sandler upped their price objective on Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright lifted their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Finally, Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $61.89.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.